Advances in the pharmacological management of breathlessness.

David C Currow, Alicia M Ward, Amy P Abernethy

Journal: Current opinion in supportive and palliative care 2009;3(2):103-6

PMID: 19333124

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

PURPOSE OF REVIEW

To explore advances in the pharmacological treatment of refractory breathlessness and the physiological evidence for treatments.

RECENT FINDINGS

The evidence for the role of oral and parenteral opioids in the reduction of breathlessness continues to strengthen from individual studies and from systematic reviews. Importantly, more data are emerging about a lack of lowering in oxygenation or carbon dioxide retention with opioid therapy. In healthy volunteers and those with refractory dyspnoea, nebulized frusemide appears to be worthy of further investigation with adequately powered phase III studies.

SUMMARY

Opioids prescribed regularly can help to predictably and safely reduce breathlessness for people with a range of end-stage illnesses.

Address: Flinders University, Daw Park, SA, Australia. [email protected]

DOI: 10.1097/SPC.0b013e32832b37fa

Link outs

Free resources

Medical:

https://medlineplus.gov/breathingproblems.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-BRIP1-5

Subscription / membership required

Full Text Sources:

MeSH Terms: Dyspnea, Furosemide, Humans, Morphine, Narcotics, Nebulizers and Vaporizers, Palliative Care, Sodium Potassium Chloride Symporter Inhibitors